BR0116014A - Polinucleotìdeo, cassete de expressão, vetor, medicamento, composição farmacêutica, uso de um polinucleotìdeo, animal transgênico, e, método de expressar um gene de interesse terapêutico in vivo - Google Patents
Polinucleotìdeo, cassete de expressão, vetor, medicamento, composição farmacêutica, uso de um polinucleotìdeo, animal transgênico, e, método de expressar um gene de interesse terapêutico in vivoInfo
- Publication number
- BR0116014A BR0116014A BR0116014-1A BR0116014A BR0116014A BR 0116014 A BR0116014 A BR 0116014A BR 0116014 A BR0116014 A BR 0116014A BR 0116014 A BR0116014 A BR 0116014A
- Authority
- BR
- Brazil
- Prior art keywords
- polynucleotide
- vivo
- expressing
- vector
- gene
- Prior art date
Links
- -1 expression cassette Substances 0.000 title abstract 4
- 238000001727 in vivo Methods 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 title abstract 4
- 108091033319 polynucleotide Proteins 0.000 title abstract 4
- 239000002157 polynucleotide Substances 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 title abstract 3
- 230000009261 transgenic effect Effects 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 2
- 102000008102 Ankyrins Human genes 0.000 abstract 1
- 108010049777 Ankyrins Proteins 0.000 abstract 1
- 108700019146 Transgenes Proteins 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
"POLINUCLEOTìDEO, CASSETE DE EXPRESSãO, VETOR, MEDICAMENTO, COMPOSIçãO FARMACêUTICA, USO DE UM POLINUCLEOTìDEO, ANIMAL TRANSGêNICO, E, MéTODO DE EXPRESSAR UM GENE DE INTERESSE TERAPêUTICO IN VIVO". A invenção diz respeito a novas seq³ências promotoras derivadas de uma porção a montante da seq³ência codificadora do gene para a proteína CARP (Proteína de Repetição da Anquirina Cardíaca), e que são capazes de controlar o nível e a especificidade da expressão de um transgene in vivo nas células do músculo cardíaco. A invenção descreve assim novas composições, construções, vetores e seus usos in vivo para a transferência e expressão de um ácido nucleico in vivo nas células do músculo cardíaco. O objeto da presente invenção também é o uso das seq³ências promotoras para gerar animais transgênicos que constituam modelos para o estudo de certas patologias cardíacas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25158200P | 2000-12-07 | 2000-12-07 | |
PCT/EP2001/015412 WO2002046220A2 (en) | 2000-12-07 | 2001-12-05 | Sequences upstream of the carp gene, vectors containing them and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0116014A true BR0116014A (pt) | 2003-10-21 |
Family
ID=22952571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0116014-1A BR0116014A (pt) | 2000-12-07 | 2001-12-05 | Polinucleotìdeo, cassete de expressão, vetor, medicamento, composição farmacêutica, uso de um polinucleotìdeo, animal transgênico, e, método de expressar um gene de interesse terapêutico in vivo |
Country Status (18)
Country | Link |
---|---|
US (3) | US7193075B2 (pt) |
EP (1) | EP1358208A2 (pt) |
JP (1) | JP2004519222A (pt) |
KR (1) | KR20030090609A (pt) |
CN (1) | CN1483040A (pt) |
AU (2) | AU2640002A (pt) |
BR (1) | BR0116014A (pt) |
CA (1) | CA2431193A1 (pt) |
CZ (1) | CZ20031569A3 (pt) |
FI (1) | FI20030851A (pt) |
IL (1) | IL156137A0 (pt) |
MX (1) | MXPA03005039A (pt) |
NO (1) | NO20032584L (pt) |
NZ (1) | NZ526408A (pt) |
PL (1) | PL365314A1 (pt) |
RU (1) | RU2283865C2 (pt) |
WO (1) | WO2002046220A2 (pt) |
ZA (1) | ZA200305184B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0410844A (pt) * | 2003-06-05 | 2006-06-27 | Centelion | fator de crescimento de fibroblasto de codificação de plasmìdeo para o tratamento de defeitos angiogênicos associados com hipercolesterolemia ou diabetes |
NZ584848A (en) * | 2007-09-28 | 2012-09-28 | Intrexon Corp | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
RU2532854C2 (ru) * | 2008-10-28 | 2014-11-10 | Пайонир Хай-Бред Интернэшнл, Инк. | Сульфонилмочевина-реактивные репрессорные белки |
RU2515926C2 (ru) * | 2009-02-04 | 2014-05-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца |
RU2497529C2 (ru) * | 2011-11-08 | 2013-11-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ стимуляции регенеративных процессов в ишемизированных тканях |
CN105779457B (zh) * | 2016-05-31 | 2019-02-12 | 北京大学 | 心肌细胞特异启动子及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5819599A (en) * | 1998-09-11 | 2000-04-03 | Regents Of The University Of California, The | Recombinant adenovirus for tissue specific expression in heart |
US6033642A (en) * | 1999-03-29 | 2000-03-07 | Starmet Corporation | Method for producing silicon tetrafluoride from uranium oxyfluoride |
-
2001
- 2001-12-05 WO PCT/EP2001/015412 patent/WO2002046220A2/en active IP Right Grant
- 2001-12-05 NZ NZ526408A patent/NZ526408A/en unknown
- 2001-12-05 PL PL01365314A patent/PL365314A1/xx not_active Application Discontinuation
- 2001-12-05 KR KR10-2003-7007662A patent/KR20030090609A/ko not_active Application Discontinuation
- 2001-12-05 IL IL15613701A patent/IL156137A0/xx unknown
- 2001-12-05 CN CNA01821309XA patent/CN1483040A/zh active Pending
- 2001-12-05 CZ CZ20031569A patent/CZ20031569A3/cs unknown
- 2001-12-05 JP JP2002547956A patent/JP2004519222A/ja not_active Withdrawn
- 2001-12-05 AU AU2640002A patent/AU2640002A/xx active Pending
- 2001-12-05 AU AU2002226400A patent/AU2002226400B2/en not_active Ceased
- 2001-12-05 BR BR0116014-1A patent/BR0116014A/pt not_active IP Right Cessation
- 2001-12-05 EP EP01995724A patent/EP1358208A2/en not_active Withdrawn
- 2001-12-05 MX MXPA03005039A patent/MXPA03005039A/es active IP Right Grant
- 2001-12-05 RU RU2003120081/13A patent/RU2283865C2/ru not_active IP Right Cessation
- 2001-12-05 CA CA002431193A patent/CA2431193A1/en not_active Abandoned
- 2001-12-07 US US10/005,337 patent/US7193075B2/en not_active Expired - Fee Related
-
2003
- 2003-06-06 FI FI20030851A patent/FI20030851A/fi unknown
- 2003-06-06 NO NO20032584A patent/NO20032584L/no not_active Application Discontinuation
- 2003-07-03 ZA ZA200305184A patent/ZA200305184B/en unknown
-
2005
- 2005-09-30 US US11/239,469 patent/US20060110362A1/en not_active Abandoned
-
2006
- 2006-08-23 US US11/508,239 patent/US20070150971A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030039984A1 (en) | 2003-02-27 |
IL156137A0 (en) | 2003-12-23 |
US20070150971A1 (en) | 2007-06-28 |
WO2002046220A3 (en) | 2003-09-04 |
NZ526408A (en) | 2005-07-29 |
US7193075B2 (en) | 2007-03-20 |
AU2002226400B2 (en) | 2006-11-02 |
NO20032584D0 (no) | 2003-06-06 |
JP2004519222A (ja) | 2004-07-02 |
CN1483040A (zh) | 2004-03-17 |
WO2002046220A9 (en) | 2007-11-08 |
CA2431193A1 (en) | 2002-06-13 |
US20060110362A1 (en) | 2006-05-25 |
RU2003120081A (ru) | 2005-01-27 |
ZA200305184B (en) | 2004-10-04 |
FI20030851A (fi) | 2003-06-06 |
KR20030090609A (ko) | 2003-11-28 |
EP1358208A2 (en) | 2003-11-05 |
AU2640002A (en) | 2002-06-18 |
NO20032584L (no) | 2003-08-05 |
PL365314A1 (en) | 2004-12-27 |
MXPA03005039A (es) | 2004-08-02 |
WO2002046220A2 (en) | 2002-06-13 |
RU2283865C2 (ru) | 2006-09-20 |
CZ20031569A3 (cs) | 2003-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Duan | Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients | |
Rockman et al. | Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. | |
Laing et al. | Expression of an inducible nitric oxide synthase gene in rainbow trout Oncorhynchus mykiss | |
ES2937058T3 (es) | Péptido que tiene actividad blanqueadora de la piel y uso del mismo | |
CN106795142A (zh) | 用于递送核酸的立体化学富集组合物 | |
EA006603B1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
GEP20022701B (en) | Modulators of Body Weight, Corresponding Nucleic Acids and Proteins, and Diagnostic and Therapeutic Uses Thereof | |
HU229959B1 (hu) | Új alkalikus proteáz-variánsok és ezeket tartalmazó mosó- és tisztítószerek | |
BR0209563A (pt) | ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente | |
Zou et al. | An FBXO40 knockout generated by CRISPR/Cas9 causes muscle hypertrophy in pigs without detectable pathological effects | |
CN101925362A (zh) | 利用两种或更多种肝细胞生长因子同工型来治疗或预防心脏病症 | |
RU2247554C2 (ru) | Косметические композиции, включающие человеческий сывороточный альбумин, полученный от трансгенных животных, неявляющихся человеком | |
BR0116014A (pt) | Polinucleotìdeo, cassete de expressão, vetor, medicamento, composição farmacêutica, uso de um polinucleotìdeo, animal transgênico, e, método de expressar um gene de interesse terapêutico in vivo | |
Davies | Equine Science | |
CN101848997B (zh) | 用于Myo-2肽多聚体和肌生成抑制素的融合蛋白表面表达载体以及由其转化的微生物 | |
Mahmoud et al. | The effect of dietary phosphorus on heat shock protein mRNAs during acute heat stress in male broiler chickens (Gallus gallus) | |
ES2957688T3 (es) | Construcción génica suicida doble e inducible y su uso en terapia génica | |
BR0017197A (pt) | Sequência de ácido nucleico, sequência de aminoácido, vetor de clonagem replicativo, célula hospedeira isolada vetor de expressão, métodos para testar uma substância como um agente terapêutico para modulação óssea em um hospedeiro, para identificar uma molécula e uma proteìna candidata envolvidas na modulação óssea, para testar quanto a atividade de hbm, para desenvolvimento farmacêutico para o tratamento de distúrbios do desenvolvimento ósseo, para tratar um distúrbio do desenvolvimento ósseo em um animal, para alterar o desenvolvimento ósseo em um hospedeiro, para tratar a osteoporose, para avaliar diagnóstico para uma predisposição genética a um distúrbio do desenvolvimento ósseo, para identificar uma predisposição genética para distúrbios do desenvolvimento ósseo, para expressar a proteìna de hbm em tecido ósseo, para amplificar um polimorfismo de nucleotìdeo, para identificar um elemento regulador de um gene de hbm e para modular densidade óssea em um paciente, ensaio de diagnóstico para distúrbios do desenvolvimento ósseo, cromossoma artificial bacteriano, segmento de ácido nucleico isolado, ácido nucleico, e, polipeptìdeo. | |
JP7140353B2 (ja) | ハイブリッドhgf遺伝子が導入されたaav(アデノ-関連ウイルス)ベクター | |
US20170042782A1 (en) | Stabilized polyribonucleotide coding for an elastic fibrous protein | |
WO2003092598A3 (en) | Treatment for pompe disease | |
AR025692A1 (es) | VECTORES ADENOVIRALES RECOMBINANTES, UN PROCESO PARA SU MANUFACTURA, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO EN EL TRATAMIENTO DE DIVERSOS TIPOS DE FIBROSIS HEPÁTICA, RENAL, PULMONAR Y CICATRICES HIPERTROFICAS | |
Schjerling | The basics of gene doping | |
Stamatoyannopoulos | Prospects for developing a molecular cure for thalassemia | |
RAY et al. | Protein and 28S ribosomal RNA fractional turnover rates in the rat heart after abdominal aortic stenosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) , Free format text: ALTERADO DE: GENCELL S.A. |
|
B25D | Requested change of name of applicant approved |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) , Free format text: ALTERADO DE: GENCELL SAS |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |